LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trial

Key Points

• Mood improvement was observed with LSD microdosing, indicating a potential new treatment option.
• Participants experienced significant changes in pharmacokinetic profiles associated with mood enhancements.
• This observational analysis included a phase 2a trial design with specific focus on mood and biomarkers.
• Further exploration is needed to assess the long-term effects and stability of these improvements.